Abstract:Significance Statement Complement factor H (CFH) dysfunction by an incomplete underlying mechanism causes various complement-mediated renal injuries. We identified metalloprotease ADAMTS7 as a novel binding protein of CFH that further degrades CFH and potentiates complement activation. ADAMTS7 deficiency alleviated CFH degradation and renal pathologies in lupus nephritis and renal ischemia-reperfusion injury in mice, but without affecting complement-dependent bactericidal activity. The investigation revealed a novel mechanism to explain CFH dysfunction in complement-mediated renal injuries. ADAMTS7 would be a promising target for anticomplement therapies that would potentially avoid increased risk of infection, which is the drawback of current strategies. Background The dysfunction of complement factor H (CFH), the main soluble complement negative regulator, potentiates various complement-induced renal injuries. However, insights into the underlying mechanism of CFH dysfunction remain limited. In this study, we investigated whether extracellular protease-mediated degradation accounts for CFH dysfunction in complement-mediated renal injuries. Methods An unbiased interactome of lupus mice kidneys identified CFH-binding protease. In vitro cleavage assay clarified CFH degradation. Pristane-induced SLE or renal ischemia-reperfusion (I/R) injury models were used in wild-type and ADAMTS7 −/− mice. Results We identified the metalloprotease ADAMTS7 as a CFH-binding protein in lupus kidneys. Moreover, the upregulation of ADAMTS7 correlated with CFH reduction in both lupus mice and patients. Mechanistically, ADAMTS7 is directly bound to CFH complement control protein (CCP) 1–4 domain and degraded CCP 1–7 domain through multiple cleavages. In mice with lupus nephritis or renal I/R injury, ADAMTS7 deficiency alleviated complement activation and related renal pathologies, but without affecting complement-mediated bactericidal activity. Adeno-associated virus–mediated CFH silencing compromised these protective effects of ADAMTS7 knockout against complement-mediated renal injuries in vivo. Conclusion ADAMTS7-mediated CFH degradation potentiates complement activation and related renal injuries. ADAMTS7 would be a promising anticomplement therapeutic target that does not increase bacterial infection risk.

ADAMTS7-Mediated Complement Factor H Degradation Potentiates Complement Activation to Contributing to Renal Injuries

ADAMTS13 Inhibits Oxidative Stress and Ameliorates Progressive Chronic Kidney Disease Following Ischaemia/reperfusion Injury.

ADAM10 Mediates Ectopic Proximal Tubule Development and Renal Fibrosis Through Notch Signalling

C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complement

E3 ligase FBXW7 aggravates TMPD-induced systemic lupus erythematosus by promoting cell apoptosis

The Dysfunctions of Complement Factor H in Lupus Nephritis.

Complement Activation Profile of Patients with Primary Focal Segmental Glomerulosclerosis.

Complement Activation in Progression of Chronic Kidney Disease.

C3a mediates epithelial-to-mesenchymal transition in proteinuric nephropathy.

Role of intracellular complement activation in kidney fibrosis

Heterozygous mutations in factor H aggravate pathological damage in a stable IgA deposition model induced by Lactobacillus casei cell wall extract

A haplotype in CFH family genes confers high risk of rare glomerular nephropathies

Proteomic analysis of laser captured tubular tissues reveals complement activation and mitochondrial dysfunction in autoimmune related kidney diseases

ADAMTS-7, a Novel Proteolytic Culprit in Vascular Remodeling.

Interaction of uromodulin and complement factor H enhances C3b inactivation.

ADAMTS-7 Inhibits Re-endothelialization of Injured Arteries and Promotes Vascular Remodeling Through Cleavage of Thrombospondin-1

Deficiency of Mouse FHR-1 Homolog, FHR-E, Accelerates Sepsis, and Acute Kidney Injury Through Enhancing the LPS-Induced Alternative Complement Pathway

ADAMTS-7: a metalloproteinase that directly binds to and degrades cartilage oligomeric matrix protein.

Therapeutic targeting of factor D and MASP3 in complement‐mediated diseases: Lessons learned from mouse studies

Anti-complement Factor H (CFH) Autoantibodies Could Delay Pristane-Induced Lupus Nephritis